Third-Party Payer Effect On Clinical Trials Still Difficult To Quantify
Executive Summary
Third-party payer policies appear to have an effect on clinical trial participation, but the impact "is difficult" to quantify, according to a draft report by Duke Evidence-Based Practice Center researchers prepared for the Agency for Healthcare Research and Quality
You may also be interested in...
Need For Blinded Payment In Randomized Trials Is Recognized In Recent Bills
Recent legislation is recognizing the need to blind patients and health care providers to sources of reimbursement in clinical trials to ensure scientifically valid results
CMS Maintains Clinical Trial Coverage Status Quo, Again
Under intense pressure from Congress, industry and the medical research community, CMS has decided to maintain the status quo for covering routine costs in clinical trials
Duke Studying Impact Of Clinical Trial Coverage On Enrollment For CMS
BALTIMORE - With anecdotal evidence suggesting that insurance coverage for treatment expenses associated with clinical trials may affect study participation, CMS has contracted with Duke University to conduct a more systematic evaluation of the issue